🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
393

Quick answer

Takeda has 393 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. TAK-625

    Takeda

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 3 small molecule completed

    1 trial

  2. TAK-667

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  3. TAK-672

    Takeda

    Acquired Hemophilia A

    phase 3 mab completed

    1 trial

  4. TAK-743 300 mg

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  5. TAK-755

    Takeda

    Thrombotic Thrombocytopenic Purpura (TTP)

    phase 3 mab active

    3 trials

  6. TAK-771

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 small molecule completed

    2 trials

  7. TAK-771

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  8. TAK-788

    Takeda

    Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  9. TAK-816

    Takeda

    Healthy Volunteers

    phase 3 mab completed

    1 trial

  10. TAK-816+ DPT-TAKEDA

    Takeda

    Immunization

    phase 3 mab completed

    1 trial

  11. TAK-861

    Takeda

    Narcolepsy Type 1

    phase 3 small molecule active

    4 trials

  12. TAK-861

    Takeda

    Narcolepsy Type 1 (NT1)

    phase 3 small molecule active

    1 trial

  13. TAK-861, TAK-861 placebo (same excipients as TAK-861)

    Takeda

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 3 small molecule active

    1 trial

  14. TAK-861, TAK-861 placebo (same excipients as TAK-861), TAK-861

    Takeda

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 3 small molecule active

    1 trial

  15. TAK-861, TAK-861 placebo (same excipients as TAK-861), TAK-861

    Takeda

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 3 small molecule active

    1 trial

  16. TAK-875

    Takeda

    Diabetic Patients

    phase 3 small molecule completed

    1 trial

  17. TAK-875

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  18. TAK-875

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  19. TAK-875

    Takeda

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  20. TAK-875

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    4 trials

  21. TAK-881

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 3 mab active

    1 trial

  22. TAK-881

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab active

    2 trials

  23. TAK-881, HyQvia 100 mg/mL solution for infusion for subcutaneous use, HyQvia 100 mg/mL solution for infusion for subcutaneous use

    Takeda

    Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  24. TAP-144-SR(6M)

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  25. TAP-144-SR(6M)

    Takeda

    Premenopausal Breast Cancer

    phase 3 small molecule completed

    1 trial

  26. TDV

    Takeda

    Dengue Fever

    phase 3 mab active

    5 trials

  27. TDV

    Takeda

    Healthy Volunteers

    phase 3 mab completed

    4 trials

  28. TED

    Takeda

    Short Bowel Syndrome

    phase 3 small molecule completed

    1 trial

  29. TVP-1012

    Takeda

    Parkinson's Disease

    phase 3 small molecule completed

    1 trial

  30. TVP-1012 1mg

    Takeda

    Parkinson's Disease

    phase 3 small molecule completed

    3 trials

  31. TachoSil®

    Takeda

    Hemorrhage

    phase 3 mab completed

    1 trial

  32. TachoSil®

    Takeda

    Cerebrospinal Fluid Leaks

    phase 3 other completed

    1 trial

  33. TachoSil®

    Takeda

    Bleeding

    phase 3 small molecule completed

    1 trial

  34. Tacrolimus

    Takeda

    Ulcerative Colitis

    phase 3 small molecule terminated

    1 trial

  35. Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)

    Takeda

    Dengue Fever

    phase 3 mab completed

    1 trial

  36. Teduglutide

    Takeda

    Short Bowel Syndrome

    phase 3 small molecule active

    13 trials

  37. Teduglutide 0.05mg/kg

    Takeda

    Short Bowel Syndrome

    phase 3 small molecule completed

    1 trial

  38. Tetravalent Dengue Vaccine (TDV)

    Takeda

    Dengue

    phase 3 mab completed

    1 trial

  39. Tetravalent Dengue Vaccine (TDV)

    Takeda

    Dengue Fever

    phase 3 mab active

    2 trials

  40. Trelagliptin 25 mg

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  41. VONVENDI

    Takeda

    Von Willebrand Disease (VWD)

    phase 3 mab active

    1 trial

  42. VPRIV ®,

    Takeda

    Gaucher Disease, Type 1

    phase 3 mab completed

    2 trials

  43. Vedolizumab

    Takeda

    Pouchitis

    phase 3 small molecule active

    1 trial

  44. Vedolizumab

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    5 trials

  45. Vedolizumab

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    9 trials

  46. Vedolizumab

    Takeda

    Primary Sclerosing Cholangitis

    phase 3 small molecule terminated

    1 trial

  47. Vedolizumab 300 mg IV

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  48. Vedolizumab IV

    Takeda

    Crohn's Disease

    phase 3 small molecule active

    2 trials

Frequently asked questions

How many pipeline programs does Takeda have?

393 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.